Leprosy and Tuberculosis: An Insight-Review

REFERENCES

• Acocella G. Human bioavailability studies. IUATLD Symposium “Quality Control of anti-tuberculosis drugs” Bull. Int. Uni. A. TB. Lung Dis. 1989; 64: 38–40
   PubMedGoogle Scholar
• Advisory Council for the Elimination of Tuberculosis. Essential components of a tuberculosis control program: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb. Mortal. Wkly. Rep. 1995; 44 RR-11: 1–16
   Google Scholar
• WHO. A guide to eliminating leprosy as a public health problem. Geneva 1995, 1st edition, WHO/LEP/95.1
   Google Scholar
• American Thoracic Society. University of Cape Town: The Mycobacteria Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb. Mortal. Wkly. Rep. 2000; 49: 1–51
   Google Scholar
• American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb. Mortal. Wkly. Rep. 2000; 49: 1–51
   Google Scholar
• Anargyros P., Astill D. S., Lim I. S. Comparison of improved BACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. J. Clin. Microbiol. 1990; 28: 1288–1291
   PubMed Web of Science ®Google Scholar
• Annals of the New York Academy of Sciences. 2001; 953: 98–105, 2001 New York Academy of Sciences
   Google Scholar
• Arnold H. L., Odom R. B., James W. D. Leprosy. Andrew's Diseases of the Skin8th. Saunders, Philadelphia 1990; 389–404
   Google Scholar
• Barnes P., Blotch A. B., Davidson B. T., Snider Jr D. E. Tuberculosis in patients with immuno-deficiency virus infection. N. Engl. J. Med. 1991; 324: 1644–1650
   PubMed Web of Science ®Google Scholar
• Barry T., Colleran G., Glennon M., Dunican L., Gannon F. The 16S-23S ribosomal spacer region as a target for DNA probes to identify eubacteria. Method. Appli. 1991; 1: 51–56
   PubMedGoogle Scholar
• Bass J. B., Farer L. S., Hopewell P. C., Jacobs R. F., Snider D. E., Jr. Diagnostic standards and classification of tuberculosis. Am. Rev. Respir. Dis. 1990; 142: 725–735
   PubMedGoogle Scholar
• BCG Vaccine. Division of Tuberculosis Elimination, National Centre for HIV, STD and TB prevention. Last Updated: April 2006. Attn: Content Manager, DTBE Web site. Centers for Disease Control and Prevention, 1600 Clifton Rd. NE Mailstop E-10. Atlanta, GA. 30333(404): 639–8135, E-mail: [email protected].
   Google Scholar
• Beck J. S., Potts R. C., Kardjito T., Grange J. M. T4 lymphopenia in patients with active pulmonary tuberculosis. Clin. Exp. Immunol. 1985; 60: 49–54
   Google Scholar
• Bergey D. H., Holt J. G., Krieg N. A. R., Sneath P. H. A. The mycobacteria. Bergey's Manual of Determinative Bacteriology9th. Lippincott Williams and Wilkins, Philadelphia 1994
   Google Scholar
• Bell R. T. Tuberculosis of the 1990s: the quiet public health threat. Pa. Med. 1992; 95: 24–25
   Google Scholar
• Bloom B. R., Murray C. J. L. Tuberculosis: commentary on a re-emergent killer. Science 1992; 257: 1055–1064
   PubMed Web of Science ®Google Scholar
• Blumberg H. M., Leonard M. K. Jr, Jasmer R. M. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293(22)2776–2784
   Web of Science ®Google Scholar
• Bonicke R. Identification of mycobacteria by biochemical methods. Bull. Un. Int. Tuber 1962; 32: 13–15
   Google Scholar
• Brennan J. P., Draper P. Ultrastructure of Mycobacterium tuberculosis. Tuberculosis: Pathogenesis, Protection, and Control, B. R. Bloom. ASM Press. 1994; 271–284
   Google Scholar
• Brennan P. J., Nikaido H. The envelope of mycobacteria. Ann. Rev. Biochem. 1995; 64: 29–63
   PubMed Web of Science ®Google Scholar
• Brief History of Tuberculosis from New Jersey Medical School National Tuberculosis Center., http://www.umdnj.edu/~ntbcweb/history.htm.
   Google Scholar
• Catanzaro A., Davidson B. L., Fujiwara P. I., Goldberg M. J., Gordin F., Salfinger M., Sbabaro J., Schluger N. W., Sierro M. F., Woods G. L. Rapid diagnostic tests for tuberculosis: what is the appropriate use?. Am. J. Respir. Crit. Care Med. 1997; 155: 1804–1814
   Google Scholar
• CDC. Core Curriculum on Tuberculosis. 2000
   Google Scholar
• CDC. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis ACET. Morb. Mortal. Wkly. Rep. 1996, 1998. 47 No. RR-13. MMWR 1996. 45 No. RR-4.
   Google Scholar
• Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. Morb. Mortal. Wkly. Rep. 1994; 43: 1–132
   Google Scholar
• Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of Advisory Council for the Elimination of Tuberculosis. Morb. Mortal Wkly. Rep. 1995; 44(RR-11)19–34
   Google Scholar
• Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. Morb. Mortal Wkly. Rep. 1994; 43: 1–132
   Google Scholar
• Chaulet P. The supply of anti-tuberculosis drugs and National drug policies. Tuberc. Lung Dis. 1992; 73: 295–304
   Google Scholar
• Chaulk C. P., Kazandjian V. A. Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 1998; 279: 943–948
   PubMed Web of Science ®Google Scholar
• Chemotherapy of leprosy for control programs—Technical Report Series No. 675. WHO.
   Google Scholar
• Chintu C., Mwinga Alwyn. An African perspective on the threat of tuberculosis and HIV/AIDS–can despair be turned to hope. Lancet 1999; 353: 997
   PubMed Web of Science ®Google Scholar
• Cole S. T. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537–543
   PubMed Web of Science ®Google Scholar
• Cole S. T., Eiglmeier K., Parkhill J., James K. D., Thomson N. R., Wheeler P. R., et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007–1011
   PubMed Web of Science ®Google Scholar
• Collins F. M. Immunology of tuberculosis. Am. Rev. Respir. Dis. 1982; 125: 542–549
   Google Scholar
• 2003. Controlling Tuberculosis in India. N. Engl. J. Med., 348(8)758–759
   Google Scholar
• Core Curriculum on Tuberculosis. What the Clinician Should Know, 4th edition. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention CDC. 2000, Internet version updated August 2003.
   Google Scholar
• Crofton J. The assessment and treatment of drug-resistance problems in tuberculosis. J. Irish Med. Assoc. 1970; 63: 75–78
   Google Scholar
• Daniel, Levy M. D. Infectious Diseases, Greater Baltimore Medical Center. Review provided by VeriMed Healthcare Network. Baltimore, MD, Ph.D.
   Google Scholar
• Davies P. D. O. Tuberculosis and migration. Clinical tuberculosis2nd, Terry L Barrett. Chapman and Hall, London 1998; 365–382
   Google Scholar
• Dennis C. Honey I shrunk the Genome, genome reduction in the leprosy bacillus. Nature Reviews Genetics.
   Google Scholar
• Dhillon G. P. Leprosy elimination in India. Bull. Lepr. Elimin. Alliance 2004; 4: 7–8
   Google Scholar
• Dhople A. M. Search for newer antileprosy drugs. Indian J. Lepr. 2000; 71: 7–22
   Google Scholar
• Division of Tuberculosis Elimination Centers for Disease Control and Prevention Fact sheets, data, and other resources. DTBE Publications Page. Division of Tuberculosis Elimination. Atlanta. 404: 639–8135, Attn: Content Manager, DTBE Website. Centers for Disease Control and Prevention, 1600 Clifton Rd., NE Mailstop E-10. GA30333
   Google Scholar
• Dolin P. J., Raviglione M. C., Kochi S. Global tuberculosis incidence and mortality during 1990–2000. Bull WHO 1994; 72: 213–220
   PubMed Web of Science ®Google Scholar
• Dormandy T. The White Death: A History of Tuberculosis. Hambledon Press, London 1999
   Google Scholar
• Dye C., Scheele S., Dolin P., Pathania V., Raviglione M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 677–686
   Google Scholar
• Efficacy of single dose multi-drug therapy for treatment of single lesion paucibacillary leprosy. Single lesion multi-centered trial group. Ind. J. Lepr. 1997; 69: 121–129
   Google Scholar
• Ezueby J. P. List of bacterial names with standing in nomenclature genus mycobacterium. J. Syst. Bacteriol, 1997, http://www.bacteio.cict-fr/m/mycobacterium. Accessed: January 15, 2007.
   Google Scholar
• Fischl M. A., Uttamchandani R. B., Daikos G. L., Poblete R. B., Moreno J. N., Reyes R. R. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann. Intern. Med. 1992; 117: 177–183
   PubMed Web of Science ®Google Scholar
• Freiden T. E., Sterling T., Pablos-Mendez A., Kilburn J. O., Cauthen J. O., Dooley S. W. The emergence of drug-resistant tuberculosis in New York city. N. Engl. J. Med. 1993; 328: 521–526
   Google Scholar
• Gebre S., Saunderson P., Byass P. Relapse after fixed duration multi-drug therapy: the AMFES cohort. Lepr. Rev. 2000; 71: 325–331
   PubMedGoogle Scholar
• Gidoh M., Tsutsumi S., Funazu T., Koide S., Narita S. On characteristic anti-inflammatory effects of several anti-leprosy drugs. Jap. J. Lepr. 1997; 48: 7–18
   Google Scholar
• Gilks C. F. The Challenge of HIV/AIDS in Sub-Saharan Africa. J. Roy. Col. Phys. Lond. 1999; 33: 180–184
   Google Scholar
• Global TB/HIV Working Group Tuberculosis & HIV., http://www.who.int/en.
   Google Scholar
• Good Fellow M., Wayne L. G. Taxonomy and nomenclature. The Biology of mycobacteria, C. Ratledge, J. Stanford. Academic Press, London 1983; 309–351, Vol. I
   Google Scholar
• Good R. C. Opportunistic pathogens in the genus mycobacterium. Ann. Rev. Microbiol. 1985; 39: 347–369
   PubMed Web of Science ®Google Scholar
• Grange J. M. Drug-resistance and tuberculosis elimination. Bull. Int. Un. A Tuber. Lung Dis. 1990; 65: 57
   Google Scholar
• Hansen's Disease Leprosy. Centre for Disease Control & Prevention. National Center for Infectious Diseases/Division of Bacterial and Mycotic Diseases. Kenneth Wener, M.D., Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA. Review provided by Veri. Med. Healthcare Network.
   Google Scholar
• Hansen's Disease Leprosy. Division of Bacterial and Mycotic Diseases Content source: National Center for Infectious Diseases/Division of Bacterial and Mycotic Diseases., http://www.cdc.gov/ncidod/dbmd/diseaseinfo/hansens_t.htm
   Google Scholar
• Ha S. J., Jeon B. Y., Youn J. I., Kim S. C., Cho S. N., Sung Y. C. Protective effect of DNA vaccine during chemotherapy on re-activation and re-infection of Mycobacterium tuberculosis. Gene Ther 2005; 12: 637–638, doi:10.1038/sj.gt.3302465.
   Google Scholar
• Horsburgh, Jr. C. Robert, Feldman Sandor, Ridzon Renee. Practice Guidelines for the Treatment of Tuberculosis. Clin. Infect. Dis. 2000; 31: 633–639
   Google Scholar
• International Association Technical Forum. Diagnosis and classification of leprosy. Report of the International Association Technical Forum. Lepr Rev 2002; 73: S17–S26
   Google Scholar
• International Leprosy Association Technical Forum. Global situation of leprosy control at the beginning of the 21st century. Report of the International Leprosy Association Technical Forum. Lepr. Rev. 2002; 73: S13–S16
   Google Scholar
• Iseman M. D. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 1993; 329: 784–791
   PubMed Web of Science ®Google Scholar
• Jacobson R. R., Krahenbuhl J. L. Leprosy. Lancet 1999; 353(9153)655–60 [Medline]
   PubMed Web of Science ®Google Scholar
• Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice. Thorax 2000; 55: 887–901
   PubMedGoogle Scholar
• Karonga Prevention Trial Group. Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet. 1996; 348: 17–24
   PubMed Web of Science ®Google Scholar
• Kaur H., Chitkara N. K. A study of mycobacteria including acid fast bacilli Culture and biochemical characteristics. Ind. J. Tuber. 1967; 12: 16–18
   Google Scholar
• Kawamura L. M., Gelber R. H. Leprosy. Cutaneous Medicine and Surgery, Vol. 2, Arndt, LeBoit, Robinson, Wintroub. WB Saunders Co, Philadelphia, Pa 1996; 993–1005
   Google Scholar
• Kent P. T., Kubica G. P. Public Health Mycobacteriology: A guide to level III laboratory. Centers for Disease Control. Atlanta 1985
   Google Scholar
• Kochi A., Vareldzis B., Styblo K. Multi-Drug resistant tuberculosis and control. Res. Microbiol. 1993; 144: 104–110
   PubMed Web of Science ®Google Scholar
• Laing R. O. 1994, Discussion of Weil, D. Drug Supply: meeting a global need in Tuberculosis: Back to the Future pp. 137–149, Eds. Porter J.D.H. and McAdam K.P.W.J. Chichester; John Wiley & Sons
   Google Scholar
• Leprosy. Med. Microbiol. 323–324, ID. 1008–1017
   Google Scholar
• Lepra India: Leprosy Facts
   Google Scholar
• Leprosy—The Disease and Its Treatment. University of Zambia Medical Library. Leprosy
   Google Scholar
• Leprosy. Elyse Harrop, MD, Editors: Terry L Barrett, Michael J Wells, Lester Libow, Catherine Quirk, Dirk M Elston. 2005
   Google Scholar
• Lockwood D.N. J., Bryceson A.D. M. Leprosy. Rook/Wilkinson/Ebling Textbook of Dermatology, R. H. Champion. Mass: Blackwell Publishing Professional, Malden 1998; 2: 1215–1235
   Google Scholar
• Mahmoudi A., Iseman M. D. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993; 270: 65–68
   PubMed Web of Science ®Google Scholar
• Meier A., Sander P., Schaper K. J., Scholz M., Bottger E. C. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1996; 40: 2452–2454
   PubMedGoogle Scholar
• Miller B., Rosenbaum S., Stange P. V., Solomon S. L., Castro K. G. Tuberculosis control in a changing health care system: model contract specifications for managed care organizations. Clin. Infect. Dis. 1998; 27: 677–686
   Google Scholar
• Miller R. A. Leprosy and AIDS: A Review of Literature and Speculations on the Impact of CD4+ Lymphocyte Depletion on Immunity to Mycobacterium leprae. Int. J. Lep. 1991; 59(4)639–644
   Google Scholar
• Minnikin D. E., Goodfellow M. Lipid composition in classification and identification of acid fast bacteria. Classification and identification, M. Goodfellow, E. G. Board. Academic Press, London 1980; 184–256, Microbiological Cl80:
   Google Scholar
• Minnikin D. E., Goodfellow M. Mycolic acid patterns in mycobacterial classification. 1954–1979 twenty five years of mycobacterial taxonomy, G. P. Kubica, K. G. Wayne, L. S. Good, Atlanta 1980; 159–170, US Department of Health Education and Welfare Center For Disease Control.
   Google Scholar
• Mitchison D. A., SelKon J. B. The bactericidal activities of anti-tuberculosis drugs. Am. Rev. Tuberc. 1956; 75: 109–123
   Google Scholar
• Mitchision D. A. The action of anti-tuberculosis drugs in short course chemotherapy. Tubercle. 1985; 66: 219–225
   Google Scholar
• Morrison N. E., Marley G. M. Clofazimine binding studies with deoxyribonucleic acid. Int. J. Lepr. 1976; 44: 475–481
   Google Scholar
• Moschella S. L., Cropley T. G. Diseases of the mononuclear phagocytic system. Dermatology3rd, S. L. Moschella, H. J. Hurley. Saunders, Philadelphia 1992; 1100–1115
   Google Scholar
• Mountains Beyond Mountains: The Quest of Dr. Paul Farmer, a Man Who Would Cure the World. A non-fiction account of treating TB in Haiti, Kidder Tracy, Peru, and elsewhere, Random House 2000. ISBN 0812973011.
   Google Scholar
• Naafs B., Pearson J. M., Wheate H. W. Reversal reactions: The prevention of permanent nerve damage. Comparison of short and long term steroid treatment. Int. J. Lepr. 1979; 47: 7–12
   Google Scholar
• Nemery B., Yew W. W., Albert R., Brun-Buisson C., Macnee W., Martinez F. J., Angus D. C., Abraham E. Tuberculosis, non-tuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004. Am. J. Respir. Crit. Care Med. 2005; 1716: 554–562
   Google Scholar
• New York State Department of Health: Disease Carriers–Bacteria: Mycobacterium tuberculosis
   Google Scholar
• Nolte F. S., Metchock B. Mycobacterium. Manual of clinical microbiology6th, P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, RH Yolken. ASM Press, Washington, DC 1995; 400–437
   Google Scholar
• Orita M., Suzu Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 875–879
   Google Scholar
• Paramasivan C. N. Status of drug resistance in Tuberculosis after the introduction of Rifampicin in India. J. Ind. Med. Assoc. 2003; 101: 154–156
   PubMedGoogle Scholar
• Pathania V., Almida J., Kochi A. TB patients and private care providers in India. 1997, WHO/TB/1997;97: 1223. http://hqlibdoc.who.int/hq/1997/WHO_TB_97.233.pdf
   Google Scholar
• Peters J. H., Gordon G. R., Murray J. F., Levy L. Minimal inhibitory concentration of dapsone for Mycobacterium leprae in rats. Antimicrob. Agents Chemother. 1975; 8: 551–557
   Google Scholar
• Prevention of disabilities and rehabilitation. Lepr. Rev. 2002; 73: S35–S43
   Google Scholar
• Questions and Answers About TB from the. Centers for Disease Control and Prevention. Division of Tuberculosis Elimination
   Google Scholar
• Rao P. S., Gift N., Rao G. S., Samuel P., Bushanam R. S. Elimination of leprosy: Integration of leprosy related activities into general health services of Tamil Nadu. Leprosy Rev. 2002; 73: 123–129
   Google Scholar
• Rattan A., Kalia A., Ahmad N. Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives. Emerging Inf. Dis. 1998; 4: 2
   Google Scholar
• Raviglione M. D., Snider D. E., Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220–226
   PubMed Web of Science ®Google Scholar
• Ridley D. S., Jopling W. H. Classification of leprosy according to immunity: a five group system. Int. J. Lep. 1966; 34: 255–267
   Google Scholar
• Runyon D. H. Annonymous mycobacteria in pulmonary disease. Med. Clin. North Amer. 1959; 43: 273–299
   PubMed Web of Science ®Google Scholar
• Runyon E. H., Selin M. J., Harris H. W. Distinguishing mycobacteria by the niacin test. Amer. Rev. Tuber. 1959; 79: 663–665
   PubMedGoogle Scholar
• Sbarbaro J., Blomberg B., Chaulet P. Fixed–Dose combination formulations for tuberculosis control. Editorial. Int. J. Tuberc. Lung Dis. 1999; 3(11)S286–S287
   Google Scholar
• Scollard D. M., Gillis T. P., Williams D. L. Polymerase chain reaction assay for the detection and identification of Mycobacterium leprae in patients in the United States. Am. J. Clin. Pathol. 1998; 109(5)642–646
   Google Scholar
• Shaila M. S., Gopinathan R. P., Ramakrishnan T. Protein synthesis Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin susceptible and resistant strains. Antimicrob. Agents Chemother. 1973; 4: 205–213
   Google Scholar
• Smith C. M., Smith W. C. Current understanding of disability prevention. Ind. J. Lepr. 2000; 73: 393–399
   Google Scholar
• Snider D. E., Jr, Roper W. L. The new tuberculosis. N. Engl. J. Med. 1992; 326: 703–705
   PubMed Web of Science ®Google Scholar
• Spence D. P. S., Hotchkiss J., Williams C. S. D., Davies P. D. O. Tuberculosis and poverty. BMJ 1993; 307: 759–761
   PubMed Web of Science ®Google Scholar
• Storrs, Eleanor E. Pandoras Box: Leprosy through the ages, http://pandoras-box.org/my05002.htm.
   Google Scholar
• Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am. Rev. Respir. Dis. 1993; 147: 1311–1320
   PubMed Web of Science ®Google Scholar
• Swaminathan S., Ramachandran R., Baskaran G., Paramasivan C. N., Ramanathan U., Venkatesan P., Prabhakar R., Dutta N. Risk of development of tuberculosis in HIV infected patients. Tuber. Lung Dis. 2000; 4: 839
   Google Scholar
• The Leprosy Mission. What Leprosy does to the face and eyes
   Google Scholar
• Thibert L., Lapierre S. Routine application of high-performance liquid chromatography for identification of mycobacteria. J. Clin. Microbiol. 1993; 31: 1759–1763
   PubMed Web of Science ®Google Scholar
• Todar K. Todar's Online Textbook of Bacteriology. Tuberculosis. University of Wisconsin-Madison Department of Bacteriology. 2005
   Google Scholar
• Tsukamura M. Identification of mycobacteria. Tubercle 1967; 48: 311–338
   PubMedGoogle Scholar
• The Stop TB Partnership international organization. World Tuberculosis Day., http://www.stoptb.org/globalplan.
   Google Scholar
• The Tuberculosis Coalition for Technical Assistance—TBCTA The main purpose of TBCTA is to assist the U.S. Agency for International Development USAID and its local public, private, NGO partners to improve TB control programs and accelerate the implementation of the Directly Observed Treatment Short Course DOTS strategy. With other global TB partners, TBCTA contributes to accelerate the pace of DOTS expansion.
   Google Scholar
• Vaccines for Development.
   Google Scholar
• Walton D., Farmer P. The New White Plague. JAMA. 2000; 284: 2789
   Google Scholar
• Tuberculosis from MedlinePlus an excellent resource for the public from US National Library of Medicine.
   Google Scholar
• Tuberculosis News., http://www.topix.net/health/tuberculosis.
   Google Scholar
• World Health Organisation. The changing face of tuberculosis: a new challenge to the developing world. World Health Organisation, Geneva 1994
   Google Scholar
• US-Mexico Border Health Commission–Against transmission of TB through the Mexican/USA border., http://www.borderhealth.org/tuberculosis.php?curr=programs.
   Google Scholar
• Washington State University, Leprosy, http://www.wsu.edu.
   Google Scholar
• Wayne L. G., Diaz G. A. Identification of mycobacteria by specific precipitation of catalase with absorbed sera. J. Clin. Microbiol. 1985; 21: 721–725
   Google Scholar
• Weil D. Drug Supply: meeting a global need in Tuberculosis. Back to the Future. J. D. H Porter, K. P. W. J McAdam. John Wiley & Sons, Chichester 1994; 123–126
   Google Scholar
• Weis S. E., Slocum P. C., Blais F. X., King B., Nunn M., Matney B. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 1994; 330: 1179–1184
   PubMed Web of Science ®Google Scholar
• WHO model prescribing information—drug used in leprosy. WHO/DMP/DSI/98.1. WHO, Geneva 1998
   Google Scholar
• WHO. Global Tuberculosis Control. Surveillance, Planning, Financing. WHO/CDC/Tuberculosis/2002. Geneva 2002
   Google Scholar
• World Health Organization. The WHO/IUATLD. Global project on anti-tuberculosis Drug Resistance Surveillance: Anti-tuberculosis drug resistance in the world. Report no.3. GenevaSwitzerland 2004, WHO/CDS/TB/2004.
   Google Scholar
• World Health Organization. Leprosy–Global situation. Weekly Epidemiological Record 2000; 75: 225–232
   Google Scholar
• WHO. A Guide to Leprosy Control. World Health Organization, GenevaSwitzerland 1980; pp. 1–47
   Google Scholar
• World Health Organisation. TB, a global emergency. World Health Organisation, Geneva 1994
   Google Scholar
• World Health Organization. Bridging the gaps: the world health report. The Organization, Geneva 1995
   Google Scholar
• World Health Organisation. WHO report on the tuberculosis epidemic. WHO, Geneva 1996
   Google Scholar
• World Health Organisation. WHO report on the tuberculosis epidemic. WHO, Geneva 1997
   Google Scholar
• World Health Organisation and IUATLD. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO, Geneva 1997; 1994–1997
   Google Scholar
• WHO/TB/97.229. WHO Drug Information. 1999; Vol. 13(No. 4.), http://www.who.int/medicines/edl.html.
   Google Scholar
• World Health Organization. Bridging the gaps: the world health report. The Organization, Geneva 1995
   Google Scholar
• World Health Organization report on TB epidemic. Global TB programme. The Organization, Geneva 1997
   Google Scholar
• World Health Organization Tuberculosis home page at World Health Organization—Strategy & Operations, Monitoring & Evaluation.
   Google Scholar
• World Health Organization. Issues Relating to the Use of BCG in Immunization Programmes-A Discussion Document. 1999
   Google Scholar
• World Health Organisation. WHO report on the tuberculosis epidemic, 1996. WHO, Geneva 1996
   Google Scholar
• World Health Organisation. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO, Geneva 1997; 1994–7
   Google Scholar
• WWW.nacoonline.org
   Google Scholar
• Yoder L. J., Guerra I E. Hansen's Disease: A Guide to Management in the United States. Hansen's Disease Foundation, Carville, La, 18–22
   Google Scholar
• Yong Kim J., Shakow A., Mate K., Vanderwarker C., Gupta R., Farmer P. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Soc. Sci. Med. 2005; 61(4)847–859
   PubMed Web of Science ®Google Scholar
• Young Douglas, B. Blueprint for the white plague. Nature 1998; 393: 515–516
   Google Scholar
• Zarir F., Udwadia. India's Multidrug-Resistant Tuberculosis Crisis. Annals of the New York Academy of Sciences. 2001; 953: 98–105
   Google Scholar
• Zumla A., Grange J. M. Doing something about tuberculosis. Br. Med. J. 1999; 318: 956 (only)
   Google Scholar